Key Dates

Related Announcements

PAR-20-214 - Research to Improve Native American Health (R21 Clinical Trials Optional)

Issued by

National Institute on Drug Abuse (NIDA)

National Institute on Minority Health and Health Disparities (NIMHD)

Purpose

The purpose of this notice is to inform interested applicants who plan to submit to Funding Opportunity Announcement (FOA) PAR-20-214 "Research to Improve Native American Health (R21 Clinical Trials Optional)" for the May, 17, 2022 deadline that, as a result of continuing hardships faced by organizations that serve Native Americans, Letters of Support from community collaborators and Indian/Native American Tribal Governments may be received by NIH as Post Submission Matrials as late as August 16, 2022. All other application materials, including Letters of Support from collaborators with academic or research organization affiliations, must be received by May 17, 2022. Changes to the funding opportunity announcement are as follows:

Section IV. Application and Submission Information

Currently Reads:

Letters of Support: If the applicant(s) is working with tribes/Tribal governments then Tribal/community resolutions of support, or equivalent documents, should accompany the application.

Revised to Read:

Letters of Support:If the applicant(s) is working with tribes/Tribal governments then Tribal/community resolutions of support, or equivalent documents, should accompany the application. For the May 17, 2022 receipt date only, Tribal Resolutions and Letters of Support from community collaborators may be submitted up through August 16, 2022 as post submission material. Note that letters of support from Key Personnel and consultants with academic or research organization affiliations must be submitted by May 17, 2022 by 5:00 PM local time of applicant organization.

Post Submission Materials

Currently Reads:

Applicants are required to follow the instructions for post-submission materials, as described inthe policy. Any instructions provided here are in addition to the instructions in the policy.

Revised to Read:

Applicants are required to follow the instructions for post-submission materials, as described in the policy. For the May 17, 2022 reciept date only: Letters of Support sent as Post submission materials must be submitted as PDFs by the Authorized Organization Representative (AOR) of the applicant organization. Although the post-submission materials may originate from the PD/PI, Contact PD/PI, or organizational officials, the AOR must send the materials directly to the SRO or must send his/her concurrence to the PD/PI who will forward the materials and concurrence to the SRO. A communication from the PD/PI only or with a "cc" to the AOR will not be accepted.

If the Letters of Support are being submitted late, each letter should contain the following:
Principal Investigator Name:
Principal Investigator email:
Principal Investigator phone number:
Title of the project:
Grant number (if available):

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kathy Etz, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-1749
Email: Ketz@nih.gov

Aria Crump, Sc.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-0881
Email:acrump@nida.nih.gov